Implied Volatility Surging for Phathom Pharmaceuticals Stock Options
What Phathom Pharmaceuticals Bears Spotted Before A 63% Slide
Phathom Pharmaceuticals to Participate in November Investor Conferences
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
Phathom Pharmaceuticals Announces $0 Payment From Eligible Commercially Insured Patients For VOQUEZNA Tablets Through BlinkRx
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Phathom (PHAT) Q3 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript
Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $310.000M-$325.000M vs $314.842M Est
Phathom Pharmaceuticals Q3 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $84.722M Miss $85.096M Estimate
Phathom Pharmaceuticals Provides Update on FDA Litigation
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14;
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.